ClearPoint Neuro 경영진
경영진 기준 점검 3/4
ClearPoint Neuro CEO는 Joe Burnett, Nov2017 에 임명되었습니다 의 임기는 8.67 년입니다. 총 연간 보상은 $2.81M, 20.8% 급여 및 79.2% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $5.35M 가치에 해당하는 회사 주식의 1.03% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.5 년과 6.8 년입니다.
핵심 정보
Joe Burnett
최고경영자
US$2.8m
총 보수
| CEO 급여 비율 | 20.75% |
| CEO 재임 기간 | 8.7yrs |
| CEO 지분 보유율 | 1.0% |
| 경영진 평균 재임 기간 | 3.5yrs |
| 이사회 평균 재임 기간 | 6.8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 26
CLPT: Accelerated Huntington’s Approval Path Will Drive Future Revenue Opportunity
Analysts have lifted their price target on ClearPoint Neuro from $20 to $25, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E in light of ClearPoint's role as a direct beneficiary of the FDA-supported path to accelerated approval for uniQure's AMT-130 in Huntington's disease. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed its earnings guidance for 2026, maintaining expected revenue in the range of US$52 million to US$56 million.Seeking Alpha • Jun 18
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case
Summary ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure’s AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT’s Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations. Valuation is premium (8.06x EV/sales), justified by 26.8% projected revenue growth, but profitability hinges on partner drug launches and cash management. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 09
CLPT: Biopharma Partnerships And Intracranial Programs Will Drive Future Upside Potential
Analysts have lifted their price target on ClearPoint Neuro by $2, reflecting updated assumptions around discount rates, profit margins, and long term price-to-earnings (P/E) expectations. What's in the News ClearPoint Neuro reaffirmed revenue guidance for 2026, maintaining an expected range of US$52 million to US$56 million.내러티브 업데이트 • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.내러티브 업데이트 • Apr 20
CLPT: Biopharma Partnerships Will Drive Future Intracranial Program Adoption
ClearPoint Neuro's analyst price target has shifted by $2 as analysts weigh the recent FDA feedback on a partner's program in relation to the company's more than 60 active biopharma relationships and multiple expedited intracranial programs. Analyst Commentary Bullish Takeaways Bullish analysts see the reset price target of $18 per share as supported by what they view as a base business valuation of $12 per share, with additional value tied to pipeline and execution on intracranial programs.내러티브 업데이트 • Apr 06
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption
Analysts have adjusted their price target on ClearPoint Neuro to $25.00, reflecting updated assumptions around the discount rate, margin expectations, and long term P/E benchmarks following recent research commentary. Analyst Commentary Recent research commentary on ClearPoint Neuro highlights a mix of optimism around the core business and caution linked to regulatory outcomes in partner programs, which feeds directly into updated valuation work and risk assumptions.내러티브 업데이트 • Mar 22
CLPT: Broad Biopharma Partnerships And Intracranial Programs Will Drive Future Upside
Analysts have raised their price target on ClearPoint Neuro to $25 from $24, citing the company’s broad base of more than 60 biopharma partners and multiple clinical-stage intracranial programs as key supports for the updated valuation framework. Analyst Commentary Recent research on ClearPoint Neuro reflects a mix of renewed optimism and lingering caution, with analysts updating their valuation work after regulatory feedback on a key partner trial and reassessing the base business.새로운 내러티브 • Mar 21
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 06
CLPT: Broad Biopharma Partnerships Will Support Future Neurology Platform Upside
Analysts have reduced their fair value estimate for ClearPoint Neuro from $29 to $24 and highlighted a lower $18 Street price target, citing higher perceived risk after the FDA feedback on a partner program, while still pointing to a broad biopharma customer base and multiple clinical-stage collaborations as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the updated valuation from more than 60 active biopharma partners, which suggests a diversified customer base rather than reliance on a single program.
새로운 내러티브 • Mar 06
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?분석 기사 • Nov 10
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
The ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price has softened a substantial 39% over the previous 30 days...분석 기사 • Nov 03
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Sep 25
Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 84% after a shaky period...분석 기사 • May 04
After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Those holding ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares would be relieved that the share price has rebounded 31% in...Seeking Alpha • Apr 29
ClearPoint Neuro: Fundamentals Continue To Strengthen
Summary ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. I continue to believe ClearPoint is an attractive investment opportunity, but its high revenue multiple, current lack of profitability and market volatility mean risk is elevated. Read the full article on Seeking Alpha
새로운 내러티브 • Mar 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.분석 기사 • Feb 14
After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have continued their recent momentum with a 25% gain in the last month...분석 기사 • Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders have had their patience rewarded with a 26% share price jump in the...분석 기사 • Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Despite an already strong run, ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have been powering on, with a gain of 28...분석 기사 • Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 26% after a shaky period...분석 기사 • May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its latest first-quarter results and things are looking bullish...Seeking Alpha • Apr 25
ClearPoint Neuro: Macro-Induced Multiple Compression
Summary ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates. The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances. The recent capital raise should be sufficient to see the ClearPoint through to profitability. ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio. Read the full article on Seeking Alpha분석 기사 • Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for ClearPoint Neuro is US$4.02 based on 2 Stage Free Cash Flow to Equity Current...분석 기사 • Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) will be pleased this week, given that the stock price is up 19...분석 기사 • Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ), is not the largest company out there, but it received a lot of attention from a...분석 기사 • Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$29m |
| Dec 31 2025 | US$3m | US$584k | -US$26m |
| Sep 30 2025 | n/a | n/a | -US$23m |
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$21m |
| Dec 31 2024 | US$3m | US$538k | -US$19m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$2m | US$518k | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$21m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$2m | US$494k | -US$16m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$1m | US$445k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$784k | US$435k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$864k | US$366k | -US$6m |
보상 대 시장: Joe의 총 보수(USD2.81M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.45M) 수준입니다.
보상과 수익: Joe의 보상은 회사가 적자임에도 증가했습니다.
CEO
Joe Burnett (49 yo)
8.7yrs
재임 기간
US$2,814,944
보수
Mr. Joseph Michael Burnett, also known as Joe, has been Chief Executive Officer, President and Director of ClearPoint Neuro, Inc. since November 7, 2017. Mr. Burnett has spent his entire career in medical...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 8.7yrs | US$2.81m | 1.03% $ 5.4m | |
| Chief Financial Officer | 5.5yrs | US$1.25m | 0.35% $ 1.8m | |
| Chief Business Officer | 3.5yrs | US$1.12m | 0.36% $ 1.9m | |
| Chief Operating Officer | 3.8yrs | 데이터 없음 | 0.22% $ 1.2m | |
| General Counsel & Secretary | 5.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Sales & Business Development | less than a year | US$305.12k | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Quality | less than a year | 데이터 없음 | 데이터 없음 |
3.5yrs
평균 재임 기간
46yo
평균 나이
경험이 풍부한 관리: CLPT의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.5 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 8.7yrs | US$2.81m | 1.03% $ 5.4m | |
| Independent Chairman of the Board | 9.2yrs | US$242.65k | 0.44% $ 2.3m | |
| Independent Director | 6.8yrs | US$207.50k | 0.24% $ 1.2m | |
| Independent Director | 5yrs | US$220.00k | 0.16% $ 833.8k | |
| Independent Director | 4.7yrs | US$200.00k | 0.22% $ 1.1m | |
| Independent Director | 12.3yrs | US$212.30k | 0.29% $ 1.5m | |
| Director | 6.3yrs | US$192.50k | 0.16% $ 811.5k |
6.8yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: CLPT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/09 12:15 |
| 종가 | 2026/07/09 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ClearPoint Neuro, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |